Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

NGM BIOPHARMACEUTICALS, INC.

(NGM)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

NGM Biopharmaceuticals : Chardan Suspends Coverage on NGM Biopharmaceuticals at Buy Rating With $44 Price Target

08/02/2021 | 11:07am EDT


ę MT Newswires 2021
All news about NGM BIOPHARMACEUTICALS, INC.
09/17NGM BIOPHARMACEUTICALS : BMO Capital Raises Price Target on NGM Biopharmaceuticals to $35 ..
MT
09/16NGM BIOPHARMACEUTICALS : Bio Presents Preliminary Findings from Ongoing Phase 1a/1b Dose E..
AQ
09/16NGM Biopharmaceuticals, Inc. Presents Preliminary Findings from Ongoing Phase 1A/1B Dos..
CI
09/13NGM BIOPHARMACEUTICALS : Stock Climbs After Raymond James Upgrade
MT
09/13NGM BIOPHARMACEUTICALS : Raymond James Upgrades NGM Biopharmaceuticals to Strong Buy From ..
MT
09/07NGM BIOPHARMACEUTICALS : B. Riley Raises NGM Biopharmaceuticals' PT to $35 from $32 Ahead ..
MT
08/23NGM BIOPHARMACEUTICALS : Developing NGM831 to Treat Cancer
MT
08/23NGM BIOPHARMACEUTICALS : Bio Discloses Fourth Oncology Development Candidate, 831, an ILT3..
AQ
08/23NGM Biopharmaceuticals, Inc. Discloses Fourth Oncology Development Candidate, NGM831, a..
CI
08/09NGM BIOPHARMACEUTICALS : BMO Capital Adjusts NGM Biopharmaceuticals' Price Target to $29 F..
MT
More news
Analyst Recommendations on NGM BIOPHARMACEUTICALS, INC.
More recommendations
Financials (USD)
Sales 2021 83,4 M - -
Net income 2021 -125 M - -
Net cash 2021 129 M - -
P/E ratio 2021 -13,7x
Yield 2021 -
Capitalization 1 718 M 1 718 M -
EV / Sales 2021 19,0x
EV / Sales 2022 30,7x
Nbr of Employees 210
Free-Float 70,5%
Chart NGM BIOPHARMACEUTICALS, INC.
Duration : Period :
NGM Biopharmaceuticals, Inc. Technical Analysis Chart | NGM | US62921N1054 | MarketScreener
Technical analysis trends NGM BIOPHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Last Close Price 22,21 $
Average target price 34,83 $
Spread / Average Target 56,8%
EPS Revisions
Managers and Directors
David J. Woodhouse Chief Executive Officer & Director
Siobhan Nolan Mangini CFO & Principal Accounting Officer
William J. Rieflin Executive Chairman
Hui Tian Vice President-Research
Marc Learned Vice President-Research Operations
Sector and Competitors
1st jan.Capi. (M$)
NGM BIOPHARMACEUTICALS, INC.-26.69%1 718
GILEAD SCIENCES, INC.20.85%88 281
BIONTECH SE276.71%74 169
WUXI APPTEC CO., LTD.35.04%69 209
REGENERON PHARMACEUTICALS28.14%64 363
VERTEX PHARMACEUTICALS-22.40%47 582